⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18551185 | 0.97 | CYP2C19 (0.48) | — | |
| SCHEMBL20003356 | 0.97 | CYP2C19 (0.48) | — | |
| SCHEMBL20003355 | 0.97 | CYP2C19 (0.48) | — | |
| SCHEMBL20733072 | 0.97 | CYP2C19 (0.48) | — | |
| SCHEMBL25569446 | 0.85 | CYP2C19 (0.62) | — | |
| SCHEMBL4745112 | 0.84 | LMNA (0.32) | — | |
| SCHEMBL17766691 | 0.84 | LMNA (0.32) | — | |
| SCHEMBL4745076 | 0.84 | LMNA (0.32) | — | |
| SCHEMBL4746164 | 0.84 | LMNA (0.32) | — | |
| SCHEMBL17766693 | 0.84 | LMNA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064769-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | PHIO PHARMACEUTICALS CORP. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2023005280-A1 | PREPARATION AND APPLICATION OF AMINOPYRIMIDINE DERIVATIVE SELECTIVELY TARGETING CDK9 | 中国药科大学 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023005281-A1 | PREPARATION METHOD FOR AND APPLICATION OF NOVEL CDK9 INHIBITOR HAVING MACROCYCLIC SKELETON STRUCTURE | 中国药科大学 | 2023-02-02 | — | — | WO | disclosed |
| WO-2022133034-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022103834-A1 | COMBINATIONS OF METAP2 INHIBITORS AND CDK4/6 INHIBITORS FOR THE TREATMENT OF CANCER | SYNDEVRX, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021178887-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR MODIFYING CAR-T CELL ACTIVITY | PURDUE RESEARCH FOUNDATION (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-3862005-A1 | NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) | Phio Pharmaceuticals Corp. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20170204086-A1 | ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2017-07-20 | — | — | US | disclosed |
| WO-2017073065-A1 | NOVEL ANTICANCER DRUG | 公益財団法人静岡県産業振興財団 | 2017-05-04 | — | — | WO | disclosed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| WO-2008100772-A1 | CHAIN EXTENDERS | ALBEMARLE CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |